A recent consensus statement by The Association for Cancer Immunotherapy (CIMT) immunoguiding program (CIP) concluded that minimally required markers of human Treg are CD3, CD4, CD25, CD127, and Foxp3 [31]. The gene discussed is FOXP3; the disease is cancer.